These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33488954)

  • 1. Novel Pyrimidinones as SHP2 Antagonists for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2021 Jan; 12(1):3-4. PubMed ID: 33488954
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
    LaRochelle JR; Fodor M; Ellegast JM; Liu X; Vemulapalli V; Mohseni M; Stams T; Buhrlage SJ; Stegmaier K; LaMarche MJ; Acker MG; Blacklow SC
    Bioorg Med Chem; 2017 Dec; 25(24):6479-6485. PubMed ID: 29089257
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.
    Sarver P; Acker M; Bagdanoff JT; Chen Z; Chen YN; Chan H; Firestone B; Fodor M; Fortanet J; Hao H; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu G; Liu S; Liu C; McNeill E; Mohseni M; Sendzik M; Stams T; Spence S; Tamez V; Tichkule R; Towler C; Wang H; Wang P; Williams SL; Yu B; LaMarche MJ
    J Med Chem; 2019 Feb; 62(4):1793-1802. PubMed ID: 30688459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
    Bagdanoff JT; Chen Z; Acker M; Chen YN; Chan H; Dore M; Firestone B; Fodor M; Fortanet J; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu S; Mohseni M; Ntaganda R; Sarver P; Smith T; Sendzik M; Stams T; Spence S; Towler C; Wang H; Wang P; Williams SL; LaMarche MJ
    J Med Chem; 2019 Feb; 62(4):1781-1792. PubMed ID: 30688462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells.
    Liu Z; Zhao Y; Fang J; Cui R; Xiao Y; Xu Q
    Oncotarget; 2017 Aug; 8(32):53518-53530. PubMed ID: 28881828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of furo[3,4-d]pyrimidinones as selective alpha1a-adrenergic receptor antagonists.
    Lagu B; Tian D; Chiu G; Nagarathnam D; Fang J; Shen Q; Forray C; Ransom RW; Chang RS; Vyas KP; Zhang K; Gluchowski C
    Bioorg Med Chem Lett; 2000 Jan; 10(2):175-8. PubMed ID: 10673105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo.
    Hu Z; Li J; Gao Q; Wei S; Yang B
    Onco Targets Ther; 2017; 10():3881-3891. PubMed ID: 28814887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.
    Li J; Kang Y; Wei L; Liu W; Tian Y; Chen B; Lin X; Li Y; Feng GS; Lu Z
    PLoS One; 2014; 9(7):e102847. PubMed ID: 25048202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
    Sha F; Gencer EB; Georgeon S; Koide A; Yasui N; Koide S; Hantschel O
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14924-9. PubMed ID: 23980151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
    Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
    Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel PROTACs for degradation of SHP2 protein.
    Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
    Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
    Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
    Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
    Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
    Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects.
    Hartman Z; Geldenhuys WJ; Agazie YM
    ACS Omega; 2020 Oct; 5(39):25113-25124. PubMed ID: 33043190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
    Sun B; Jensen NR; Chung D; Yang M; LaRue AC; Cheung HW; Wang Q
    Am J Cancer Res; 2019; 9(1):145-159. PubMed ID: 30755818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma.
    Hu ZQ; Ma R; Zhang CM; Li J; Li L; Hu ZT; Gao QI; Li WM
    Oncol Lett; 2015 Sep; 10(3):1507-1512. PubMed ID: 26622699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functions of Shp2 in cancer.
    Zhang J; Zhang F; Niu R
    J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
    Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
    J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3.
    Qi C; Han T; Tang H; Huang K; Min J; Li J; Ding X; Xu Z
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.